HEAL Initiative: Justice Community Overdose Innovation Network (JCOIN) - Phase II Coordination and Translation Center (U2C Clinical Trial Optional)

The summary for the HEAL Initiative: Justice Community Overdose Innovation Network (JCOIN) - Phase II Coordination and Translation Center (U2C Clinical Trial Optional) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

HEAL Initiative: Justice Community Overdose Innovation Network (JCOIN) - Phase II Coordination and Translation Center (U2C Clinical Trial Optional): The intersection of criminal-legal and community-based health systems is a critical target for addressing the overdose crisis. To support research on effective interventions and implementation strategies, the National Institute on Drug Abuse intends to continue the Justice Community Overdose Innovation Network (JCOIN) Phase II. The purpose of the network is to bring together a national consortium of investigators and practitioner partners to conduct an array of research and capacity building activities to address the overdose epidemic among individuals involved in the criminal-legal system. The structure of the network shall consist of three highly integrated components - (1) Research Hubs; (2) a single, central Coordination and Translation Center; and (3) a single, central Methodology and Advanced Analytics Resource Center. This NOFO solicits applications for a Coordination and Translation Center. This NOFO runs in parallel with a companion NOFO for the Methodology and Advanced Analytics Resource Center (NOT-DA-24-068); a NOFO for Research Hubs is anticipated at a future date (NOT-DA-25-025).

Federal Grant Title:	HEAL Initiative: Justice Community Overdose Innovation Network (JCOIN) - Phase II Coordination and Translation Center (U2C Clinical Trial Optional)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Education Health Income Security and Social Services
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-DA-24-069
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.279, 93.865
CFDA Descriptions:	Information not provided
Current Application Deadline:	October 30th, 2023
Original Application Deadline:	October 30th, 2023
Posted Date:	August 21st, 2023
Creation Date:	August 21st, 2023
Archive Date:	December 5th, 2023
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	August 21st, 2023

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement: https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-069.html
Grant Announcement Contact: NIH Grants Information
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Similar Government Grants: • Imaging - Science Track Award for Research Transition (I/START) (R03 Clinical Trial Option...; • Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/...; • Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clini...; • Advancing Research on Molecular Targets and Mechanisms that Influence the Interplay Betwee...; • Advancing Research on Molecular Targets and Mechanisms that Influence the Interplay Betwee...; • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards; • Drug Abuse Aspects of Hiv/Aids and Other Infections; • Epidemiology of Drug Abuse
More Grants from the National Institutes of Health: • HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allow...; • Cellular Models of HIV Pathogenesis within NIDDK Mission Areas (R01 Clinical Trial Not All...; • U.S.-South Africa Program for Collaborative Biomedical Research Phase 3 (HIV/AIDS) (R01 C...; • Imaging - Science Track Award for Research Transition (I/START) (R03 Clinical Trial Option...; • Research Centers in Minority Institutions (RCMI) (U54 - Clinical Trial Optional)